ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "corticosteroids"

  • Abstract Number: 0810 • ACR Convergence 2024

    Glucocorticoids in Pregnancy and Lactation: Results of the Systematic Review Informing the EULAR Task Force on Antirheumatic Drugs in Reproduction, Pregnancy and Lactation

    Sabrina Hamroun1, Andrea Pluma2, Linda Rüegg3, Malte Kramer4, Yvette Meissner5, Axel Finckh6 and Frauke Foerger7, 1Cochin University Hospital, Paris, Ile-de-France, France, 2Vall d'Hebron University Hospital, Barcelona, Spain, 3Inselspital, Bern University Hospital, Bern, Switzerland, 4German Rheumatism Research Centre Berlin, Epidemiology and Health Services Research, Berlin, Germany, 5Deutsches Rheuma-Forschungszentrum, Berlin, Germany, 6Geneva University Hospital, Geneva, Switzerland, 7University hospital Bern /Inselspital Bern, Bern, Switzerland

    Background/Purpose: The management of women with musculoskeletal disorders during pregnancy and lactation presents many challenges. Since the first EULAR points to consider for the use…
  • Abstract Number: 2046 • ACR Convergence 2024

    Duration of Disease and Long-term Outcomes in Patients with Difficult-to-treat Recurrent Pericarditis: A Chronic Condition Treated with NSAIDs, Colchicine, Corticosteroids, and Anti-IL-1 Agents

    Antonio Brucato1, Elisa Ceriani2, Francesco Agozzino3, Silvia Berra4, Antonio Gidaro2, Silvia Macchi5, Letizia Vena5, Paolo Bindi5, Alberto Pavarani6, Francesco Moda7, Ludovico Luca Sicignano8, Celeste Murace8, Elena Verrecchia8, Caterina Chiara Decarlini9, Silvia Maestroni10, Gabriella Marinaro4, Lucia Trotta3, Massimo Pancrazi3, Lisa Serati3, Enrica Negro3, Claudia Gabiati3, Elisa Calabrò3, Angela Mauro11, Luisa Carrozzo3, Emanuele Bizzi3 and Massimo Imazio12, 1Department of Biomedical and Clinical Sciences, University of Milano, Department of Internal Medicine, Ospedale Fatebeneratelli, Milano, Milano, Lombardia, Italy, 2Department of Internal Medicine, Ospedale Luigi Sacco, Milano, Milan, Italy, 3Department of Internal Medicine, Ospedale Fatebeneratelli, Milano, Milan, Italy, 4Department of Internal Medicine, Ospedale Fatebeneratelli, Milano, Milano, Italy, 5University of Milano, Milan, Italy, 6University of Milano, Milan, 7Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy, 8Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Rome, Italy, 9Cardiology Division, Cardiovascular Department, San L. Mandic Hospital, Merate, Lecco, Italy, 10Internal Medicine Department, Papa Giovanni XXIII Hospital, Bergamo, Bergamo, Italy, 11Pediatric Rheumatology Unit, Department of Childhood and Developmental Medicine, Fatebenefratelli-Sacco Hospital, Milan, Italy, 12University of Udine, and Cardiothoracic Department, University Hospital Santa Maria della Misericordia, Udine, Milan, Italy

    Background/Purpose: Recurrent pericarditis (RP) challenges pts and clinicians in terms of long-term management. Objective of this study was to evaluate the remission rate (drug-free for…
  • Abstract Number: 0939 • ACR Convergence 2024

    A Joint-targeting Peptide Enhances the Therapeutic Efficacy of Liposomal Drug Delivery in Experimental Rheumatoid Arthritis

    Hemalatha Nanjaiah, Rakeshchandra Meka, Bodhraj Acharya, Shivaprasad Venkatesha and Kamal Moudgil, University of Maryland School of Medicine, Baltimore, Baltimore, MD

    Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease of synovial joints, and it affects over 1 per cent of the population worldwide. Uncontrolled or…
  • Abstract Number: 2394 • ACR Convergence 2024

    Perioperative Stress Dose vs Therapeutic Dose Comparison: One-Month Postoperative Outcomes in Moderate and Major Surgeries for Systemic Lupus Erythematous and Rheumatoid Arthritis

    Diana Gavilanes1, Alex Jakubiak2, Jhon. F Martinez3 and Anas Atrash4, 1UPMC Health Plan - Harrisburg Pa, Harrisburg, PA, 2Drexel University, Philadelphia, PA, 3BaylorScott&White Health, Waco, TX, 4UPMC Health Plan - Harrisburg Pa, Harrisburg, PA

    Background/Purpose: Major and moderate surgeries are more common in patients with autoimmune diseases. However, there is limited data available regarding the use of standard doses…
  • Abstract Number: L04 • ACR Convergence 2023

    EP-104IAR (Extended-Release Fluticasone Propionate for Injectable Suspension): Topline and Key Secondary Results from a Phase 2 Randomized, Double-blind, Vehicle-Controlled Trial in Subjects with Knee Osteoarthritis

    James Helliwell1, Amanda Malone1, Mark Kowalski2, Asger Reinstrup Bihlet3, Claire Miller4, Alejandro Castillo Mondragon5, Yanqi Li6, Christine Dobek7, Vik Peck1, Mike Wilmink8 and Lee Simon9, 1Eupraxia Pharmaceuticals, Victoria, BC, Canada, 2Eupraxia Pharmaceuticals, Winchester, VA, 3NBCD A/S, Soeborg, Denmark, 4NBCD A/S, Copenhagen, Denmark, 5NBCD, Copenhagen, Denmark, 6NBCD A/S, Soborg, Denmark, 7Eupraxia Pharmaceuticals, Edmonton, AB, Canada, 8OrthoArizona, Phoenix, AZ, 9SDG LLC, Cambridge, MA

    Background/Purpose: EP-104IAR is being developed to treat OA symptoms. Previous results from non-clinical studies evaluating local joint safety in beagle dogs, in contrast to other…
  • Abstract Number: L19 • ACR Convergence 2023

    A Phase 3 Study of Repeat Injection of TLC599 in Osteoarthritis of the Knee: Benefits to 52 Weeks

    George Spencer-Green1, David Hunter2, Thomas Schnitzer3, Sheue-Fang Shih4, Tien-Tzu Tai4, Cathy Kao4 and Siao-Ning Huang4, 1Taiwan Liposome Company, Cambridge, MA, 2Sydney Musculoskeletal Health, University of Sydney, St Leonards, New South Wales, Australia, 3Northwestern University Feinberg School of Medicine, Chicago, IL, 4Taiwan Liposome Company, Taipei, Taiwan (Republic of China)

    Background/Purpose: In osteoarthritis (OA) of the knee, intraarticular injections of corticosteroids can relieve pain, reduce inflammation, and improve mobility, but the effect is not predictable,…
  • Abstract Number: 1840 • ACR Convergence 2023

    Value of Various Intra-Articular Injections for Knee Osteoarthritis Management

    Hanna Mass1, Jamie Collins1, david Hunter2, Catherine Yang1, Morgan Jones1, Stephen Messier3, Tuhina Neogi4, A. David Paltiel5, Jeffrey Katz1 and Elena Losina6, 1Brigham and Women's Hospital, Boston, MA, 2Sydney Musculoskeletal Health, University of Sydney, St. Leonards, Australia, 3Wake Forest University, Winston-Salem, NC, 4Boston University School of Medicine, Boston, MA, 5Yale School of Public health, New Haven, CT, 6Brigham and Women's Hospital, Boston, MA

    Background/Purpose: Intra-articular injections (IAI) are commonly used to relieve pain and delay total knee replacement (TKR) in persons with knee OA. Despite higher costs and…
  • Abstract Number: 1988 • ACR Convergence 2023

    Extended-Release versus Immediate-Release Triamcinolone Acetonide for Osteoarthritis of the Knee with Comorbid Diabetes Type 2 Diabetes Mellitus: A Post Hoc Analysis

    Andrew Spitzer1, Helena Rodbard2, Sheikh Usman Iqbal3, Masato Nakazawa3, Mary DiGiorgi3 and Roy Winston3, 1Cedars-Sinai Medical Center, Los Angeles, CA, 2Endocrine and Metabolic Consultants, Rockville, MD, 3Pacira BioSciences, Inc., Tampa, FL

    Background/Purpose: Intraarticular (IA) corticosteroids are generally considered safe and effective to treat osteoarthritis of the knee (OAK) but may cause hyperglycemia that may last for…
  • Abstract Number: 2307 • ACR Convergence 2023

    Comparing Social Vulnerability Index to Area Deprivation Index to Patient Outcomes in SLE and Glucocorticoid Utilization

    Avira Som1, Lily McMorrow1, Ling Chen1, Deepali Sen2, Elizabeth Baker3 and Alfred Kim4, 1Washington University School of Medicine in St. Louis, St. Louis, MO, 2Washington University in St. Louis, St. Louis, MO, 3Saint Louis University, St. Louis, MO, 4Washington University School of Medicine, St. Louis, MO

    Background/Purpose: As shown in previous studies, outcomes in SLE are affected by social determinants of health which influence health care disparities. Evaluating health disparities through…
  • Abstract Number: 2498 • ACR Convergence 2023

    Does Physical Activity Modify the Relationship Between Pain and Corticosteroid Injection Utilization in Adults with or at High Risk for Knee Osteoarthritis?

    Sydney Liles1, Daniel White2, Thomas Bye2 and Jason Jakiela2, 1University of Delaware, Elkton, MD, 2University of Delaware, Newark, DE

    Background/Purpose: Knee osteoarthritis (OA) is a leading global cause of pain and disability, with no current cure. Knee pain is the most common symptom and…
  • Abstract Number: 0208 • ACR Convergence 2023

    Pneumocystis Jirovecii Pneumonia (PJP) Prophylaxis (PPX), Investigating the Practice Patterns of Providers for Patients on Chronic, High-Dose Immunosuppression in a Rural Integrated Health System

    Angela Bobak1, Emely Pimentel1, Jordan Jackson2, Celia Gray3, Hema Srinivasan3, Andrea Berger3 and David Bulbin3, 1Geisinger Medical Center Internal Medicine Residency, Danville, PA, 2Geisinger Medical Center Medicine-Pediatrics Residency, Danville, PA, 3Geisinger Health System, Danville, PA

    Background/Purpose: PJP is an opportunistic fungus causing significant morbidity and mortality in immunocompromised patients.  Guidelines describe PJP PPX indications among non-HIV infected individuals with cancer…
  • Abstract Number: 0587 • ACR Convergence 2023

    Impact of up to 24 Months Intravenous (IV) Belimumab (BEL) Treatment on Steroid Use and Disease Activity in Patients with SLE in Clinical Practice: Additional Post Hoc Pooled Analysis of Multicountry OBSErve Cohort Data

    Daniel Moldaver1, Seth Anderson2, Marguerite Bracher3, Roger A. Levy4, Holly A. Quasny5, Robert Wood6, Rosie Wild6, Alexandra Cusmano6 and Elke Rottier6, 1GlaxoSmithKline, Value Evidence and Outcomes, Ontario, Canada, 2GlaxoSmithKline, Value Evidence and Outcomes, Collegeville, PA, 3GlaxoSmithKline, Value Evidence and Outcomes, Stevenage, United Kingdom, 4GlaxoSmithKline, Global Medical Affairs, Collegeville, PA, 5GlaxoSmithKline, Research & Development, Durham, NC, 6Adelphi Real World, Real-World Evidence, Cheshire, United Kingdom

    Background/Purpose: The clinical effectiveness of 6-month IV BEL use in SLE has previously been described in a post hoc pooled analysis from six OBSErve cohort…
  • Abstract Number: 0678 • ACR Convergence 2023

    Benralizumab in Eosinophilic Granulomatosis with Polyangiitis

    Adrien Cottu1, Matthieu Groh2, Charlène Desaintjean3, Sylvain Marchand-Adam4, Loic Guillevin5, Xavier Puéchal6, Estibaliz Lazaro7, Maxime Samson8, Camille Taillé9, Cécile-Audrey Durel10, Elisabeth Diot11, Sarah Nicolas11, Laurent Guilleminault12, Mikael Ebbo13, Pascal Cathébras14, Clairelyne Dupin9, Halil Yildiz15, Nabil Belfeki16, Gregory Pugnet17, Pierre Chauvin18, Stephane Jouneau19, François Lifermann20, Jean-Philippe Martellosio21, Vincent Cottin22 and Benjamin Terrier23, 1Department of Internal Medicine, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France, 2National Referral Center for Hypereosinophilic Syndrome (CEREO), Hôpital Foch, Suresnes, France, 3Department of Respiratory Diseases, Hôpital Louis Pradel, Lyon, France, 4CHRU Tours, service de pneumologie et d'explorations fonctionnelles respiratoires, Tours, France, 5University Paris Descartes, Paris, France, 6National Referral Center for Rare Systemic Autoimmune Diseases, Paris, France, 7Bordeaux Hospital University, Pessac, France, 8Department of Internal Medicine and Clinical Immunology, Dijon University Hospital, Dijon, France, 9AP-HP, Bichat Hospital, Reference Center for Rare Pulmonary Diseases and University of Paris Cité, Inserm 1152, Paris, France, 10CHU Lyon, Lyon, France, 11Service de médecine interne et immunologie clinique, CHU Tours, Tours, France, 12Department of respiratory and allergic diseases, Toulouse University Hospital Center, Toulouse, France, 13Aix Marseille Univ, APHM, hôpital de la Timone, Internal Medicine Department, Marseille, France, 14Department of Internal medicine, Hôpital Nord, CHU St Etienne, Saint-Etienne, France, 15Saint Luc Hospital, Bruxelles, Belgium, 16Service de Médecine Interne et Immunologie Clinique. Groupe Hospitalier Sud Île de France, Melun, France, 17CHU Toulouse Rangueil Service de Medecine Interne et Immunologie Clinique, Toulouse, France, 18Department of Respiratory Diseases, Rennes University Hospital, Rennes, France, 19Amicus, Boca Raton, FL, 20Department of Internal Medicine, Centre Hospitalier de Dax, Dax, France, 21Service de médecine interne, maladies infectieuses et tropicales, CHU de Poitiers, Poitiers, France, 22Coordinating Reference Center for Rare Pulmonary Diseases, Louis Pradel Hospital, University of Lyon, INRAE, Lyon, France, 23Department of Internal Medicine, Hôpital Cochin, AP-HP, Paris, France

    Background/Purpose: Gucocorticoid (GC)-dependant asthma and ENT exacerbations may persist in more than 80% of eosinophilic granulomatosis with polyangiitis (EGPA). The MIRRA trial demonstrated the efficacy…
  • Abstract Number: 0725 • ACR Convergence 2023

    Real-life Use of the PEXIVAS Reduced-dose Glucocorticoid Regimen in Granulomatosis with Polyangiitis and Microscopic Polyangiitis

    Sophie Nagle1, Yann Nguyen2, Xavier Puéchal3, Dimitri Titeca-Beauport4, Thomas Crépin5, Rafik Mesbah6, Idris Boudhabhay7, Gregory Pugnet8, Juliette Woessner9, Roderau Outh10, Céline Lebas11, Antoine Néel12, alexandre Karras13, Eric Hachulla11, Benjamin Subran14, Philippe Kerschen15, Mathieu Gerfaud-Valentin16, Stéphane Vinzio17, Tiphaine Goulenok18, Raphael Borie19, Sébastien Humbert20, Yurdagul Uzunhan21, Sarah Melboucy-Belkhir22, Jean-Baptiste Gouin23, Mary-Jane Guerry24 and Benjamin Terrier25, 1AP-HP Cochin Hospital, Paris, France, 2Department of Internal Medicine, Hôpital Beaujon, AP-HP, Clichy, France., Montmorency, France, 3National Referral Center for Rare Systemic Autoimmune Diseases, Paris, France, 4CHU Amiens, Amiens, France, 5Amiens University Hospital, Amiens, France, 6Boulogne Hospital (CH), Boulogne, France, 7Necker University Hospital, Paris, France, 8CHU Toulouse Rangueil Service de Medecine Interne et Immunologie Clinique, Toulouse, France, 9Avignon Hospital (CH), Avignon, France, 10Perpignan Hospital (CH), Perpignan, France, 11Lille University Hospital, Lille, France, 12CHU Nantes, Nantes, France, 13HEGP - APHP, Paris, France, 14Croix Saint Simon Hospital, Paris, France, 15Department of Neurology, Luxembourg Hospital Center, Luxembourg City, Luxembourg, 16Lyon University Hospital, Lyon, France, 17Grenoble Hospital (CH), Grenoble, France, 18Assistance Publique Hopitaux de Paris, Paris, France, 19Bichat-Claude Bernard, Universite de Paris, Paris, France, 20Besançon University Hospital, Besançon, France, 21AP-HP, Bobigny, France, 22Saint Quentin Hospital, Saint-Quentin, France, 23Vannes Hospital (CH Bretagne Atlantique), Vannes, France, 24Valenciennes Hospital (CH), Valenciennes, France, 25Department of Internal Medicine, Hôpital Cochin, AP-HP, Paris, France

    Background/Purpose: Glucocorticoids (GCs) in combination with rituximab (RTX) or cyclophosphamide are the cornerstone of treatment for patients with severe granulomatosis with polyangiitis (GPA) and microscopic…
  • Abstract Number: 0990 • ACR Convergence 2023

    Association of Treatment and Disease Activity with Antibiotic Use and Hospitalized Infection Among People Living with Rheumatoid Arthritis: Baseline Data from a Longitudinal Study in the ArthritisPower Registry

    Kelly Gavigan1, Esteban Rivera2, Odette Kolenky3, Cassie Clinton4, Emily Holladay4, David Curtis5, Laura Stradford6, Jeffrey Curtis4, W. Benjamin Nowell6, Christian Curtis7 and Michael George8, 1Global Healthy Living Foundation, Upper Nyack, NY, 2Global Healthy Living Foundation, Long Island City, NY, 3Hospital of the University of Pennsylvania, Philadelphia, PA, 4University of Alabama at Birmingham, Birmingham, AL, 5Global Healthy Living Foundation, San Francisco, CA, 6Global Healthy Living Foundation, Nyack, NY, 7Illumination Health, Birmingham, AL, 8University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Infections are a major contributor to morbidity and mortality in patients (pts) with rheumatoid arthritis (RA). Little is known about the risk of non-serious…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • …
  • 13
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology